2. Others NF-κB Metabolic Enzyme/Protease Immunology/Inflammation Apoptosis
  3. Drug Intermediate Reactive Oxygen Species (ROS) Apoptosis Keap1-Nrf2 Heme Oxygenase (HO) Bcl-2 Family Caspase
  4. D-Leucine amide-CDDO-Me-HMP

D-Leucine amide-CDDO-Me-HMP is a prodrug composed of CDDO-Me (HY-13324) and ligustrazine (HY-N0264). D-Leucine amide-CDDO-Me-HMP can protect against CCl4-induced liver injury. D-Leucine amide-CDDO-Me-HMP can inhibit ROS production, alleviates mitochondrial damage and inhibits cell apoptosis. D-Leucine amide-CDDO-Me-HMP can be used for the research of liver injury.

For research use only. We do not sell to patients.

D-Leucine amide-CDDO-Me-HMP

D-Leucine amide-CDDO-Me-HMP Chemical Structure

CAS No. : 2749600-16-4

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

D-Leucine amide-CDDO-Me-HMP Related Antibodies

Top Publications Citing Use of Products

View All Heme Oxygenase (HO) Isoform Specific Products:

View All Isoforms
HO-1 HO-2

View All Bcl-2 Family Isoform Specific Products:

View All Isoforms
Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3 Bad

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

D-Leucine amide-CDDO-Me-HMP is a prodrug composed of CDDO-Me (HY-13324) and ligustrazine (HY-N0264). D-Leucine amide-CDDO-Me-HMP can protect against CCl4-induced liver injury. D-Leucine amide-CDDO-Me-HMP can inhibit ROS production, alleviates mitochondrial damage and inhibits cell apoptosis. D-Leucine amide-CDDO-Me-HMP can be used for the research of liver injury[1].

In Vitro

D-Leucine amide-CDDO-Me-HMP (CHL) (0.05-0.10 μM, 24 h) significantly enhances cell viability in CCl4-induced LO2 and RAW264.7 liver injury cell models[1].
D-Leucine amide-CDDO-Me-HMP (0.05-0.10 μM, 24 h) reduces ROS levels, alleviates mitochondrial damage and inhibits cell apoptosis in CCl4-induced LO2 and RAW264.7 liver injury cell models[1].
D-Leucine amide-CDDO-Me-HMP (0.10 μM, 24 h) significantly upregulates the expression of Nrf2 and HO-1 proteins in CCl4-induced LO2 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

D-Leucine amide-CDDO-Me-HMP Related Antibodies

Cell Viability Assay[1]

Cell Line: CCl4 induced LO2 and RAW264.7 liver injury cells
Concentration: 0.05 and 0.10 μM
Incubation Time: 24 h
Result: Showed cell viability of 98.4% in LO2 cells and 92.6% in RAW264.7 cells.

Immunofluorescence[1]

Cell Line: CCl4 induced LO2 and RAW264.7 liver injury cells
Concentration: 0.05 and 0.10 μM
Incubation Time: 24 h
Result: Reduced the fluorescence intensity of DCF.
Reduced the fluorescence intensity of J-monomer and Increased the fluorescence intensity of J-aggregate.
In Vivo

D-Leucine amide-CDDO-Me-HMP (CHL) (15-30 mg/kg, i.p., administered after CCl4-induced liver injury) improves liver tissue morphology and pathological damage in C57BL/6 mouse liver injury models induced by CCl4[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 (8 weeks of age, 18–20 g, CCl4-induced liver injury)[1]
Dosage: 15 mg/kg, 30 mg/kg
Administration: Intraperitoneally injection
Result: Reduced serum levels of ALT and AST.
Alleviated steatosis and inflammatory infiltration.
Upregulated the expression of HO-1 (4.2-fold) and NQO1 (5.5-fold) in liver tissue.
Downregulated the expression of p-p65 (5-fold) and pro-apoptotic protein BAX.
Upregulated the expression of anti-apoptotic protein Bcl-2, and inhibited excessive activation of Caspase-3.
Molecular Weight

876.18

Formula

C53H73N5O6
CAS No.
SMILES

[H][C@@]12CC(C)(CC[C@@]1(CC[C@]3([C@@]4(CC[C@]5(C(C)(C(OCC6=CC=C(C=C6)NC([C@@H](CC(C)C)N)=O)=C(C([C@@]5(C4=CC([C@]23[H])=O)C)OCC7=NC(C)=C(N=C7C)C)C#N)C)[H])C)C)C(OC)=O)C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

D-Leucine amide-CDDO-Me-HMP Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

D-Leucine amide-CDDO-Me-HMP2749600-16-4Drug IntermediateReactive Oxygen Species (ROS)ApoptosisKeap1-Nrf2Heme Oxygenase (HO)Bcl-2 FamilyCaspaseDrug IintermediateHeme OxygenaseLO2RAW264.7Nrf2HO-1Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
D-Leucine amide-CDDO-Me-HMP
Cat. No.:
HY-179613
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.